AutoTissue

Executive Summary

AutoTissue is a German biotechnology company pioneering cell-free implants for cardiovascular tissue engineering. By eliminating the need for long-term immunosuppression or anticoagulation, their innovative biological devices aim to significantly improve quality of life for younger patients with congenital heart defects or acquired cardiovascular diseases. The company leverages proprietary extracellular matrix technology to create implants that integrate seamlessly with host tissue, promoting regeneration rather than replacement. This approach addresses a critical unmet need in pediatric cardiology, where lifelong medication adherence and adverse side effects remain major challenges. Founded in 2017 and based in Berlin, AutoTissue is currently in the preclinical to early clinical stage. The global market for cardiovascular tissue engineering is projected to exceed $10 billion by 2030, driven by rising prevalence of heart disease and demand for durable, regenerative solutions. AutoTissue's competitive advantage lies in its cell-free platform, which simplifies manufacturing, reduces regulatory hurdles, and lowers cost. With strong IP positioning and a focus on first-in-human studies, the company is poised to attract strategic partnerships or funding to advance its lead candidate toward clinical validation. If successful, AutoTissue could redefine standard of care for pediatric cardiovascular repair.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation65% success
• Q2 2026Publication of preclinical efficacy data in peer-reviewed journal80% success
• Q3 2026Strategic collaboration or licensing deal with a cardiovascular device company50% success